Suppr超能文献

血蓝蛋白偶联肽来源于丙型肝炎病毒糖蛋白,可诱导 BALB/c 小鼠产生中和抗体。

Keyhole Limpet Hemocyanin-Conjugated Peptides from Hepatitis C Virus Glycoproteins Elicit Neutralizing Antibodies in BALB/c Mice.

机构信息

Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510380, China.

School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou 510006, China.

出版信息

J Immunol Res. 2021 Jan 16;2021:3108157. doi: 10.1155/2021/3108157. eCollection 2021.

Abstract

Currently, no vaccine to prevent hepatitis C virus (HCV) infection is available. A major challenge in developing an HCV vaccine is the high diversity of HCV sequences. The purpose of immunization with viral glycoproteins is to induce a potent and long-lasting cellular and humoral immune response. However, this strategy only achieves limited protection, and antigen selection plays a crucial role in vaccine design. In this study, we investigated the humoral immune responses induced by intraperitoneal injection of keyhole limpet hemocyanin conjugated with 4 highly conserved peptides, including amino acids [aa]317-325 from E1 and aa418-429, aa502-518, and aa685-693 from E2, or 3 peptides from hypervariable region 1 (HVR1) of E2, including the N terminus of HVR1 (N-HVR1, aa384-396), C terminus of HVR1 (C-HVR1, aa397-410), and HVR1 in BALB/c mice. The neutralizing activity against HCV genotypes 1-6 was assessed using the cell culture HCV (HCVcc) system. The results showed that the 4 conserved peptides efficiently induced antibodies with potent neutralizing activity against 3 or 4 genotypes. Antibodies induced by aa685-693 conferred potent protection (>50%) against genotypes 2, 4, and 5. Peptide N-HVR1 elicited antibodies with the most potent neutralization activities against 3 HCV genotypes: TNcc(1a), S52(3a), and ED43(4a). These findings suggested that peptides within HCV glycoproteins could serve as potent immunogens for vaccine design and development.

摘要

目前,尚无预防丙型肝炎病毒(HCV)感染的疫苗。开发 HCV 疫苗的主要挑战是 HCV 序列的高度多样性。用病毒糖蛋白进行免疫接种的目的是诱导有效的、持久的细胞和体液免疫应答。然而,这种策略仅能实现有限的保护,而抗原选择在疫苗设计中起着至关重要的作用。在本研究中,我们研究了腹腔内注射与 4 个高度保守肽(包括 E1 中的氨基酸 [aa]317-325 和 aa418-429、E2 中的 aa502-518 和 aa685-693)或来自 E2 的高变区 1(HVR1)的 3 个肽(包括 HVR1 的 N 端(N-HVR1,aa384-396)、HVR1 的 C 端(C-HVR1,aa397-410)和 HVR1)诱导的体液免疫应答。使用细胞培养 HCV(HCVcc)系统评估了针对 HCV 基因型 1-6 的中和活性。结果表明,这 4 个保守肽能够有效地诱导针对 3 种或 4 种基因型具有强大中和活性的抗体。aa685-693 诱导的抗体对基因型 2、4 和 5 具有强大的保护作用(>50%)。肽 N-HVR1 诱导的抗体对 3 种 HCV 基因型(TNcc[1a]、S52[3a]和 ED43[4a])具有最强的中和活性。这些发现表明 HCV 糖蛋白中的肽可作为疫苗设计和开发的有效免疫原。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83c4/7834783/61de69dda8cf/JIR2021-3108157.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验